The Börgeson Lab is focused on understanding and modulating human immunometabolism, with particular emphasis on the mechanisms driving cardiometabolic diseases. Our team has shown that promoting the resolution of inflammation—specifically through the administration of lipoxin lipids—can attenuate obesity-related disease in experimental models and offer protection against cardiovascular events.
We are currently exploring the therapeutic potential of lipoxins to enhance endogenous inflammation resolution in patient-specific tissues and immune cells, with the aim of reducing the burden of cardiometabolic disease. Our findings suggest that a patient’s baseline inflammatory status may influence treatment outcomes, underscoring the importance of a personalized medicine approach. Ongoing work also seeks to unravel the molecular mechanisms involved, using patient-derived ex vivo cultures of cells and tissues, alongside biobanked human samples.